Aurobindo Pharma on Tuesday informed stock exchanges that the company, as well as other firms in the US generic drug industry, are facing a second lawsuit for violation of antitrust laws.
Second US lawsuit brought against Aurobindo Pharma
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain